What Albertsons Purchase of Rite Aid Means for Drug Retail
Albertsons is buying a big portion of Rite Aid to create a company worth $24 Billion. Shares of Rite Aid soared as much as 8 percent on the news. This acquisition comes as many retailers join forces to compete with Amazon, which is involved in nearly every industry from retail, to grocery, and now even healthcare. Wall Street Journal Reporter Heather Haddon and Bold Media's Business Editor David Grasso explain what this deal means for drug retail.
"Rite Aid was really put at a disadvantage right after the stuttered Walgreens deal," says Haddon. "This was really about Rite Aid helping to reposition themselves, get access to a whole new market of Albertsons customers, and in turn Albertsons gets a lot of pharmacy customers and cross-marketing opportunities."
"We are seeing a lot of disruption, and everyone is shaking in their boots," says Grasso. "It's all about survival.
Through this deal the integrated company will operate 4,900 locations, 4,350 pharmacy counters, and 320 clinics across 38 states and Washington, D.C.
Tony Edward discusses Ethereum’s rise, governance of corporate crypto treasuries, the newly signed GENIUS Act, and the pending CLARITY Market Structure Act.
The Ether Machine, led by CEO David Merin, announces a $1.5B SPAC IPO. The firm holds 400K ETH, making it the largest Ethereum treasury holder globally.
President Donald Trump pulled a rabbit out of his trade war hat this week, announcing a trade deal with Japan putting 15% tariffs on most Japanese imports.
Nextdoor CEO Nirav Tolia shares how the neighborhood app's redesign aims to inform, connect, and protect communities with smarter features and local insight.
Tim Bohen dives into the 'Trump Trade,' renewed tariffs, waning uncertainty, corporate guidance, and what the Fed’s next move means for traders and markets.
Wall Street icon Peter Tuchman dives into Apex Trader Funding’s partnership with Wall Street Global Trading Academy and what it means for the next-gen trader.
Matthew Frankel, contributing analyst at The Motley Fool, discusses the recent SPAC resurgence, investor interest, and what the data says about their future.
